Tryp Therapeutics Inc is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, for the treatment of diseases with unmet medical needs. Tryp's program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain, and other indications. The company operates in two reportable segments; the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in the United States.
